The post discusses a successful hair loss treatment involving a hair transplant, finasteride, and minoxidil. The user underwent a 2000 graft hair transplant at the hairline in a clinic in Sweden.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
The conversation emphasizes the importance of starting hair loss treatment early, using options like minoxidil, finasteride, RU58841, essential oils, and dermarolling, and encourages leaving the hair loss subreddit once treatment begins to avoid stress and obsession. Users shared personal success with finasteride and the motivation to start treatment to prevent future regret.
PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.
25-year-old male with Norwood 2 hair loss tried PRP injections without success. Dermatologists didn't recommend finasteride or minoxidil, but suggested PRP + Mesotherapy for 50% improvement.
The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
The conversation discusses a hair loss treatment regimen involving dutasteride, pyrilutamide, oral minoxidil, and microneedling, with the aim of suppressing DHT and stimulating hair growth. Users debate the effectiveness and potential side effects of these treatments, noting that individual results may vary and that no treatment is foolproof.
Combining PRP with topical minoxidil 5% and finasteride 0.25% for hair loss treatment. One user reported success using minoxidil and finasteride with micro-needling, but not PRP.
A 25-year-old is using 1mg oral finasteride daily, 2.5mg oral minoxidil daily, and ketoconazole shampoo twice a week for hair loss, with little to no side effects. They experienced initial shedding but have seen positive results and plan to resume microneedling.
Topical dutasteride with microneedling and mesotherapy dutasteride injections are effective treatments for androgenetic alopecia in both men and women. These methods offer promising alternatives to oral therapies with potentially fewer systemic side effects.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
A man used finasteride, minoxidil, and a derma pen for a year to improve hair growth with no significant side effects. He plans to continue the treatment and explore new options.
A user is experiencing worsening hair loss despite using finasteride, PRP treatments, and supplements like vitamin D, biotin, zinc, and iron. They are seeking advice on whether to continue with finasteride, increase the dosage, or try additional PRP sessions.
Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.
The conversation discusses the effectiveness of Dutasteride mesotherapy for hair loss treatment in Germany. The user is considering trying it and seeks opinions from others who have experience with it.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
The user started a new hair loss treatment regimen using topical finasteride and minoxidil, saw palmetto, sulforaphane, and apple extract supplements, while also trying to quit nicotine and fast food. They later cut out supplements due to cost, continued with topical treatment, and experienced improved hair health but faced issues with low libido.
The user underwent a hair transplant in Boston, initially dissatisfied with the results, but later achieved significant improvement in hair density and natural appearance after consulting a different surgeon. They used finasteride, minoxidil, and low-level laser therapy as part of their treatment.
A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.